The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a pan-Canadian Oncology Biosimilars Initiative, which aims to ensure appropriate implementation and cost-effective use of therapeutic oncology biosimilars across Canada. In November 2018 the initiative held a pan-Canadian Oncology Biosimilars Summit. The initiative has released a summit proceedings report and an initiative action plan.

Separately, Health Canada announced that it is collaborating with the Drug Safety and Effectiveness Network on a project to study patients with inflammatory rheumatic diseases and inflammatory bowel disease who are taking biologic drugs.(1) The study aims to compare the safety and effectiveness of biosimilar drugs to the reference biologic drug.


(1) The protocol for the study is available here.

This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.